EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Adjunctive use of posaconazole, hyperbaric oxygen therapy, and methylene blue for COVID-19-associated mucormycosis

Sujata Mohanty, Neeraj Bansal, Anjali Verma, Hemavathy S, Arpit Gupta, Chayanika Sharma

Oral and Maxillofacial Surgery · 2025

DOI: 10.1007/s10006-025-01419-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Oral and Maxillofacial Surgery, 2025. Verfasst von Sujata Mohanty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Hauptthemen laut MEDLINE: Antifungal Agents, COVID-19, Hyperbaric Oxygenation, Methylene Blue. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The study aimed to assess the cumulative role of oral posaconazole, post-debridement Hyperbaric Oxygen (HBO) therapy, along with local application and steam inhalation with methylene blue as an adjunct to surgery to prevent further progression of COVID-19 associated sino-maxillary or mandibular mucormycosis. METHODS: A retrospective observational study was conducted on patients diagnosed with sino-maxillary or mandibular mucormycosis associated with COVID-19. A total of 38 patients underwent surgical debridement and received adjunctive treatment with posaconazole, hyperbaric oxygen therapy, and local application and steam inhalation of methylene blue. Medical records were analyzed for COVID-19-related hyperglycemia, prolonged hospitalization, immunosuppressive/steroid therapy, and the use of iron or zinc supplements, which may be linked to increased mucormycosis incidence. Outcomes were evaluated for association with any concurrent infection, complications, need for sequential debridement, and further progression of disease. RESULTS: A total of 38 patients (range: 23-68) were included, comprising 24 males and 14 females. Isolated sino-maxillary involvement was observed in 32 cases (84.21%), and mandibular involvement in 5 cases (13.15%). No further disease progression was noted during the 2-year follow-up, based on clinical evaluation and postoperative computed tomography (CT) scans. Actinomycosis co-infection was identified in 21.05% of cases. Complications included wound dehiscence (39.47%), pus discharge (5.26%), reversible hearing impairment during HBO therapy (5.26%), and flap necrosis (2.63%). Four patients (10.52%) required sequential surgical debridement for sequestrum removal. CONCLUSION: It was concluded that concurrent use of oral posaconazole, adjunct HBO therapy and methylene blue prevents further progression of COVID-19 associated sino-maxillary and mandibular mucormycosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCOVID-19Hyperbaric OxygenationMethylene BlueMucormycosisTriazolesAdultAgedFemaleHumansMaleMiddle AgedYoung AdultCombined Modality TherapyDebridementRetrospective Studies

Stichwörter der Autor:innen

Antifungal agentsHyperbaric oxygenationMethylene blueMucormycosisOsteomyelitis

Substanzen

Antifungal AgentsMethylene BlueposaconazoleTriazoles

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India.
  • Department of Oral and Maxillofacial Surgery, Maulana Azad Institute of Dental Sciences, Bahadur Shah Zafar Marg, New Delhi, 110002, India. doc.neerajbansal@gmail.com.
  • Department of Oral and Maxillofacial Surgery, Manav Rachna Dental College, Manav Rachna International Institute of Research and Studies (MRIIRS), Sector 43, Aravalli Hills, Faridabad, 121004, Haryana, India. doc.neerajb…
  • Department of Oral and Maxillofacial Surgery, ESIC Dental College, Rohini Sector 15, Delhi, 110089, India.

Zitieren

APA

Mohanty, S., Bansal, N., Verma, A., S, H., Gupta, A., & Sharma, C. (2025). Adjunctive use of posaconazole, hyperbaric oxygen therapy, and methylene blue for COVID-19-associated mucormycosis. Oral and Maxillofacial Surgery. https://doi.org/10.1007/s10006-025-01419-2

Vancouver

Mohanty S, Bansal N, Verma A, S H, Gupta A, Sharma C. Adjunctive use of posaconazole, hyperbaric oxygen therapy, and methylene blue for COVID-19-associated mucormycosis. Oral and Maxillofacial Surgery. 2025. doi:10.1007/s10006-025-01419-2

BibTeX
@article{Mohanty2025,
  author = {Mohanty, Sujata and Bansal, Neeraj and Verma, Anjali and S, Hemavathy and Gupta, Arpit and Sharma, Chayanika},
  title = {Adjunctive use of posaconazole, hyperbaric oxygen therapy, and methylene blue for COVID-19-associated mucormycosis},
  journal = {Oral and Maxillofacial Surgery},
  year = {2025},
  doi = {10.1007/s10006-025-01419-2}
}
Kostenlos starten →